7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 
      
    		                    
      revenue
    		41,630,000 47,397,000 46,850,000 56,406,000 65,200,000 73,400,000 64,179,000 74,141,000 66,865,000 68,914,000 79,025,000 204,713,000 191,263,000 242,732,000 244,293,000 228,444,000 204,810,000 217,775,000 148,211,000  
      yoy
    		-36.15% -35.43% -27.00% -23.92% -2.49% 6.51% -18.79% -63.78% -65.04% -71.61% -67.65% -10.39% -6.61% 11.46% 64.83%      
      qoq
    		-12.17% 1.17% -16.94% -13.49% -11.17% 14.37% -13.44% 10.88% -2.97% -12.79% -61.40% 7.03% -21.20% -0.64% 6.94% 11.54% -5.95% 46.94%   
      cost of revenue
    		35,975,000 39,629,000 39,125,000 37,444,000 36,826,000 38,271,000 38,335,000 35,108,000 36,686,000 43,273,000 33,676,000 53,253,000 38,176,000 37,496,000 40,032,000 40,633,000 32,047,000 37,513,000 30,368,000  
      gross profit
    		5,655,000                    
      yoy
    		                    
      qoq
    		                    
      gross margin %
    		13.58% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%  
      operating expenses:
    		                    
      selling, general and administrative
    		35,396,000 38,575,000 39,564,000 41,243,000 39,087,000 40,556,000 40,885,000 38,478,000 38,864,000 35,377,000 38,671,000 37,203,000 30,795,000 28,061,000 33,200,000 27,553,000 25,189,000 24,085,000 23,237,000  
      research and development
    		3,844,000 4,882,000 4,888,000 4,561,000 4,344,000 5,284,000 5,032,000 4,594,000 4,347,000 4,194,000 4,145,000 5,011,000 5,389,000 4,274,000 3,695,000 9,173,000 1,950,000 1,932,000 2,164,000  
      change in estimated fair value of contingent consideration
    		60,000 140,000  -630,000 -178,000 -1,195,000  -3,355,000 2,385,000 -2,316,000    -7,800,000       
      goodwill impairment
    		 30,449,000 12,435,000 11,912,000 154,239,000                
      restructuring
    		7,386,000   6,000 -4,000 -4,000 -1,212,000              
      total operating expenses
    		46,686,000 113,675,000 96,012,000 94,536,000 234,314,000 82,912,000 83,040,000 81,291,000 82,282,000 80,528,000 76,492,000 95,467,000 74,360,000 62,031,000 76,927,000 77,359,000 47,937,000 63,530,000 55,769,000  
      income from operations
    		-41,031,000 -66,278,000 -49,162,000 -38,130,000 -169,114,000 -9,512,000 -18,861,000 -7,150,000 -15,417,000 -11,614,000 2,533,000 109,246,000 116,903,000 180,701,000 167,366,000 151,085,000 156,873,000 154,245,000 92,442,000  
      yoy
    		-75.74% 596.78% 160.65% 433.29% 996.93% -18.10% -844.61% -106.54% -113.19% -106.43% -98.49% -27.69% -25.48% 17.15% 81.05%      
      qoq
    		-38.09% 34.82% 28.93% -77.45% 1677.90% -49.57% 163.79% -53.62% 32.74% -558.51% -97.68% -6.55% -35.31% 7.97% 10.78% -3.69% 1.70% 66.86%   
      operating margin %
    		-98.56% -139.84% -104.93% -67.60% -259.38% -12.96% -29.39% -9.64% -23.06% -16.85% 3.21% 53.37% 61.12% 74.44% 68.51% 66.14% 76.59% 70.83% 62.37%  
      other income:
    		                    
      interest expense
    		-6,844,000 -6,815,000 -6,778,000 -11,263,000 -13,634,000 -11,939,000 -10,864,000 -15,400,000 -11,637,000 -7,022,000 -11,833,000 -10,180,000 -3,136,000 -4,434,000 -2,664,000 -4,433,000 -8,545,000 -8,512,000 -8,770,000  
      interest income
    		2,797,000 3,030,000 3,225,000 6,036,000 7,071,000 7,086,000 7,210,000 7,459,000 7,432,000 6,791,000 6,045,000          
      change in payable to related parties pursuant to the tax receivable agreement
    		   -1,000 -39,000   671,228,000 -1,007,000 101,000 -1,436,000 -6,442,000         
      other income
    		-71,000 -4,062,000 24,000 43,000 72,000 -2,562,000 106,000 49,000 66,000 -1,620,000 168,000 914,000 -4,000 -1,275,000 7,000 201,000 78,000 -3,000 3,000  
      income before income taxes
    		-45,149,000 -74,125,000 -52,691,000 -46,502,000 -175,644,000 -16,927,000 -22,409,000 656,186,000 -20,563,000 -13,364,000 -4,523,000 95,876,000 113,763,000 174,992,000 166,841,000 143,822,000 151,652,000 145,730,000 89,561,000  
      income tax (benefit) expense
    		-92,000       -2,514,250 -5,461,000 -1,421,000 -3,175,000          
      net income
    		-45,057,000 -69,837,000 -52,853,000 -46,495,000 -175,955,000 -14,492,000 -22,680,000 -109,982,000 -15,102,000 -11,943,000 -1,348,000 87,429,000 99,653,000 156,721,000 146,860,000 126,244,000 132,810,000 134,344,000 75,852,000  
      yoy
    		-74.39% 381.90% 133.04% -57.72% 1065.11% 21.34% 1582.49% -225.80% -115.15% -107.62% -100.92% -30.75% -24.97% 16.66% 93.61%      
      qoq
    		-35.48% 32.13% 13.67% -73.58% 1114.15% -36.10% -79.38% 628.26% 26.45% 785.98% -101.54% -12.27% -36.41% 6.71% 16.33% -4.94% -1.14% 77.11%   
      net income margin %
    		-108.23% -147.34% -112.81% -82.43% -269.87% -19.74% -35.34% -148.34% -22.59% -17.33% -1.71% 42.71% 52.10% 64.57% 60.12% 55.26% 64.85% 61.69% 51.18%  
      net income attributable to non-controlling interests
    		-19,501,000 -30,246,000 -22,908,000 -20,350,000 -76,917,000 -6,907,000 -10,602,000 -4,023,000 -8,640,000 -5,402,000 -1,281,000 49,795,000 55,184,000 85,481,000 79,998,000 70,803,000 78,536,000 85,269,000 52,605,000  
      net income attributable to maravai lifesciences holdings, inc.
    		-25,556,000 -39,591,000 -29,945,000 -26,145,000 -99,038,000 -7,585,000 -12,078,000 -105,959,000 -6,462,000 -6,541,000 -67,000 37,634,000 44,469,000 71,240,000 66,862,000 55,441,000 54,274,000 49,075,000 23,247,000  
      net income per class a common share attributable to maravai lifesciences holdings, inc., basic and diluted
    		-180 -270 -210 -217.5 -700 -50 -90              
      weighted-average number of class a common shares outstanding, basic and diluted
    		144,683,000 144,236,000 143,425,000  141,555,000 135,842,000 132,333,000              
      income tax benefit
    		 -4,288,000  -463,250 311,000 -2,435,000 271,000         17,578,000 18,842,000 11,386,000   
      income tax expense
    		  162,000         8,447,000 14,110,000 18,271,000 19,981,000    13,709,000  
      loss on extinguishment of debt
    		              -208,000      
      net income per class a common share attributable to maravai lifesciences holdings, inc.:
    		                    
      basic
    		       -800 -50 -50 0 280 340 540 510 430 460 440 240  
      diluted
    		       -800 -50 -50 0 300 340 530 500 420 450 440 240  
      weighted-average number of class a common shares outstanding:
    		                    
      basic
    		   137,906,000    131,919,000 131,930,000 131,864,000 131,739,000 131,545,000 131,540,000 131,524,000 131,489,000 114,791,000 118,433,000 112,203,530,000 96,646,515,000  
      diluted
    		   137,906,000    131,919,000 131,930,000 131,864,000 131,739,000 255,323,000 131,651,000 255,361,000 255,287,000 257,803,000 258,028,000 112,280,375,000 96,672,968,000  
      gain on sale of business
    		                -11,249,000    
      change in payable to related parties pursuant to a tax receivable agreement
    		              2,340,000 -3,031,000 3,246,000  5,886,000  
      gain on sale and leaseback transaction
    		                    
      net income per class a common share/unit attributable to maravai lifesciences holdings, inc.:
    		                    
      basic
    		       -800 -50 -50 0 280 340 540 510 430 460 440 240  
      diluted
    		       -800 -50 -50 0 300 340 530 500 420 450 440 240  
      weighted-average number of class a common shares/units outstanding:
    		                    
      basic
    		   137,906,000    131,919,000 131,930,000 131,864,000 131,739,000 131,545,000 131,540,000 131,524,000 131,489,000 114,791,000 118,433,000 112,203,530,000 96,646,515,000  
      diluted
    		   137,906,000    131,919,000 131,930,000 131,864,000 131,739,000 255,323,000 131,651,000 255,361,000 255,287,000 257,803,000 258,028,000 112,280,375,000 96,672,968,000  
      
    		                    
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.